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SUMMARY
Transcriptional deregulation plays a major role in acute myeloid leukemia, and therefore identification of
epigenetic modifying enzymes essential for the maintenance of oncogenic transcription programs holds
the key to better understanding of the biology and designing effective therapeutic strategies for the disease.
Here we provide experimental evidence for the functional involvement and therapeutic potential of targeting
PRMT1, an H4R3 methyltransferase, in various MLL and non-MLL leukemias. PRMT1 is necessary but not
sufficient for leukemic transformation, which requires co-recruitment of KDM4C, an H3K9 demethylase, by
chimeric transcription factors to mediate epigenetic reprogramming. Pharmacological inhibition of
KDM4C/PRMT1 suppresses transcription and transformation ability of MLL fusions andMOZ-TIF2, revealing
a tractable aberrant epigenetic circuitry mediated by KDM4C and PRMT1 in acute leukemia.
INTRODUCTION
Human leukemia is characterized by the prevalence of recurrent
chromosomal translocations, resulting in the generation of
chimeric fusion proteins with aberrant oncogenic activities
(Look, 1997). Successful therapeutic exploitation of BCR-ABL
fusion in chronic myeloid leukemia (CML) by the small molecular
inhibitor imatinib has become the paradigm of targeted therapy
(Kantarjian et al., 2002). In contrast, there has been very little
progress in targeting classically intractable oncogenic transcrip-
tion factors, which are the common drivers for many other malig-
nancies including acute myeloid leukemia (AML) (Zeisig et al.,
2012). With the exception of acute promyelocytic leukemia
(APL) for which targeted therapy has been developed, trans-
forming it from a highly fatal disease to a manageable condition
(Arteaga et al., 2015;Wang andChen, 2008), all AML patients still
receive the same chemotherapy treatment developed more than
half a century ago, which only induces long-term complete
remission in less than 40% of young patients and is generally
too toxic to use in patients aged older than 60 years (Zeisig
et al., 2012). Therefore, there is an urgent need to understand
the underlying transformation mechanisms and develop better
therapeutic strategies for AML.
In contrast to kinases that already have functional enzymatic
activities, transcription factors need to work in tandemwith other
co-factors to orchestrate an array of epigenetic modifications for
regulating gene expression. Among these factors are protein
methyltransferases (PMTs), consisting of lysine methyltrans-
ferases (KMTs) and arginine methyltransferases (PRMTs),
which have recently taken the center stage as key players in
Significance
While the recent launch of phase I clinical trials with protein-methyltransferase (PMT) inhibitors has ignited the enthusiasm
for targeting oncogenic transcription factors, our understanding of the functions of PMTs in cancer development is still in its
infancy. This has limited the potential for exploiting this group of promising targets. Here, we reveal critical functions and
preclinical in vivo evidence for targeting a second class of PMTs, PRMT, and histone demethylases (KDMs) in cancer.
PRMT1 is necessary but not sufficient for leukemia induction by chimeric transcription factors, which also recruit
KDM4C, for epigenetic reprogramming. Genetic or pharmacological inhibition of KDM4C/PRMT1 suppresses transcription
and transformation abilities of the MOZ-TIF2 and MLL fusions, providing druggable therapeutic targets and molecular in-
sights for the development of epigenetic therapy.
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Figure 1. Targeting of Prmt1 Suppresses MLL-GAS7 Leukemia
(A) Effect of Prmt1 knockdown on serial replating of transformed cells induced by various leukemic fusions. qRT-PCR analysis of Prmt1 knockdown in leukemic
cells. Scale bars represent 0.5 cm.
(legend continued on next page)
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transcription regulation during both normal and disease devel-
opment (Abdel-Wahab and Levine, 2013; Cheung and So,
2011; Kouzarides, 2007). The involvements and therapeutic po-
tential of targeting PMTs in human cancer were initially illustrated
in MLL leukemia where the recruitments of DOT1L by MLL-AF10
(Okada et al., 2005) and PRMT1 by MLL-EEN (Cheung et al.,
2007) were required for transcriptional deregulation and cellular
transformation. Since then, additional members of the PMT fam-
ily have been reported to be involved in different cancers (Camp-
bell and Tummino, 2014; Cheung and So, 2011; Shih et al.,
2012). The promise of targeting PMTs for cancer treatment has
been highlighted by the successful development of chemical in-
hibitors against DOT1L for MLL leukemia (Daigle et al., 2011) and
EZH2 for B-cell lymphoma carrying EZH2-activating mutations
(Knutson et al., 2012; McCabe et al., 2012); these are now
entering phase I clinical trials.
Despite the success in development of inhibitors, the field is
still in its infancy and the involvements of PMTs, in particular
PRMTs, in other leukemias are still largely unexplored. More
importantly, we have very little knowledge about the mecha-
nisms and molecular networks that underpin the oncogenic
functions mediated by these individual PMTs. The discovery of
JmjC domain-containing lysine demethylases (KDMs) has pro-
vided unique insights into dynamic regulation of histone methyl-
ation for gene regulation. KDMs can work together with specific
KMTs to remove the opposing methylation marks to reinforce
particular epigenetic programs for gene expression (Cloos
et al., 2008). Consistent with this, a recent study reported an
important role of KDM5B in suppressing the epigenetic program
and function of leukemic stem cells, while its therapeutic value
has yet to be demonstrated by pharmacological means (Wong
et al., 2015). On the other hand, members of KDMs including
JHDM1B (He et al., 2011) and JMJD1C (Sroczynska et al.,
2014) have been shown to be required for leukemic transforma-
tion. In spite of these interesting observations indicating impor-
tant and contrasting roles of KDMs in leukemogenesis, very little
is known about their actual functions and underlying mecha-
nisms. It is not clear whether and how the dynamic functional
interplay between PMTs and KDMs takes part in regulating this
critical process. More importantly, in contrast to the recent
demonstration of specific in vivo efficacy of poly(ADP ribose) po-
lymerase (PARP) inhibitors in certain subtypes of AML (Esposito
et al., 2015), there have been no in vivo pharmacological inhibitor
data showing the potential value of targeting KDMs for leukemia
suppression. Together, these have significantly hindered the
potential translation of these findings into the relevant clinical
utility. Therefore, elucidation of the functional and mechanistic
involvement of histone methylation machinery will shed light on
the ongoing efforts to understand the mechanisms underlying
the roles of these different epigenetic modifying enzymes in
cancer biology, and the development of effective therapeutic
strategies targeting the associated oncogenic transcription fac-
tors in human cancer.
RESULTS
Identification of Prmt1-Dependent Leukemia Fusion
Proteins
To define the functional involvement of Prmt1 in leukemias, we
performed a systematic functional screen by retroviral transduc-
tion and transformation assay (RTTA) using validated Prmt1
small hairpin RNAs (shRNAs) on more than ten different MLL
and non-MLL oncogenic transcription factors. As a control,
downregulation of Prmt1 suppressedMLL-EEN-mediated trans-
formation of primary c-kit enriched hematopoietic stem/progen-
itor cells (HSPCs) (Cheung et al., 2007). While transformation
mediated by most of the other MLL fusions were not affected
by Prmt1 knockdown, MLL-GAS7 (So et al., 2003a) and MOZ-
TIF2 (Huntly et al., 2004) exhibited high degrees of Prmt1 depen-
dence, resulting in a significant suppression of colony formation
(Figure 1A). These data were reproduced using an independent
Prmt1 shRNA (shPrmt1#2) (Figures S1A and S1B). In line with
the RTTA data, suppression of Prmt1 resulted in an increased
differentiation (Figure S1C), cell-cycle arrest particularly at G1
checkpoint (Figure S1D), and an enhanced apoptosis (Fig-
ure S1E) in both MLL-GAS7 and MOZ-TIF2 transformed cells.
Discovery of additional Prmt1-dependent oncogenic fusions
prompted us to speculate whether they utilized similar epige-
netic machinery and, hence, recruitment of communal transcrip-
tion complexes to transform HSPC. Consistent with this idea,
GAS7 WW domain has been proposed to interact with Sam68
and PSF (Ingham et al., 2005), which are the key components
of MLL-EEN/Prmt1 transcriptional complex (Cheung et al.,
2007). To this end, both in vitro glutathione S-transferase (GST)
(B) GST pull-down assays to show the interaction of GAS7 WW domain (WW) with Sam68, PSF, and Prmt1 in vitro.
(C and D) Co-immunoprecipitation of FLAG-MLL-GAS7 with myc-tagged Prmt1, Sam68, and PSF (C) and endogenous Sam68, Prmt1, and PSF (D).
(E) ChIP analysis on the effect of Prmt1 knockdown on H4R3me2as mark and Prmt1 binding in Hoxa9 promoter and gene body region of MLL-GAS7 and
E2A-PBX.
(F) qRT-PCR analysis on Hoxa9 and Meis1 expression in MLL-GAS7 after Prmt1 knockdown.
(G) MLL-GAS7 leukemic cells transduced with control or shPrmt1 lentivirus expressing GFP markers. Transduced populations were sorted based on GFP
expression and plated into methylcellulose to study colony-forming ability.
(H) Prmt1 knockdown was validated by qRT-PCR, and its effect on H4R3me2as marks was analyzed by western blot with histone H3 as the loading control.
(I) Kaplan-Meier survival analysis of the effect of Prmt1 knockdown on MLL-GAS7 leukemogenesis (log-rank test p < 0.0001). Median disease latency: control,
30 days; shPrmt1, undefined.
(J) Kaplan-Meier survival analysis of mice transplanted with wild type (WT) or Prmt1 knockout (KO) MLL-GAS7 leukemia cells (log-rank test p = 0.0027). Median
disease latency: WT, 29 days; Prmt1 KO, undefined.
(K) Western blot analysis of H4R3me2as and H3K4me3 after AMI-408 treatment with histone H3 control for histone loading.
(L) Effect of AMI-408 on colony formation of murine leukemia cell lines.
(M) Kaplan-Meier survival analysis on the effect of AMI-408 treatment on MLL-GAS7 leukemogenesis (log-rank test p = 0.0341). Median disease latency: control,
21 days; AMI-408, 27.5 days.
All data shown are mean and SD (n = 3) unless otherwise specified. See also Figure S1. For all figures, asterisks indicate *p < 0.05, **p < 0.01, and ***p < 0.001;
ns, not significant.
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pull-down using GAS7 WW domain (Figure 1B) and immunopre-
cipitation assay by co-expression of candidate proteins (Fig-
ure 1C) had successfully demonstrated the ability of GAS7 to
recruit Sam68, PSF, and Prmt1. In addition, we also confirmed
in vivo interactions between MLL-GAS7 and the endogenous
Sam68, PSF, and Prmt1 by immunoprecipitation experiments
using antibodies specific to the endogenous proteins (Figure 1D).
To further evaluate the in vivo interaction in the context of chro-
matin and their epigenetic functions, we deployed chromatin
immunoprecipitation (ChIP) to demonstrate the specific binding
of Prmt1 and the associated asymmetric H4R3 dimethylation
(H4R3me2as) activation mark to the downstream targets of
MLL fusion, Hoxa9 (Figure 1E). As a result, we were able to
detect significant enhancements of Prmt1 binding and the
associated H4R3me2as marks in both the promoter and gene
body regions of Hoxa9 in MLL-GAS7 transformed cells but
not in the E2A-PBX control (Figure 1E). Conversely, loss of
Prmt1 through shRNA-mediated knockdown resulted in a
reduction of H4R3me2as mark (Figure 1E) and the suppressed
expression of MLL downstream targets (Figure 1F), confirming
a critical function of Prmt1 in MLL-GAS7-mediated transcription
deregulation.
PRMT1 Is Required for Maintenance of MLL-GAS7
Leukemia
To investigate whether Prmt1 is required for not only initiation
(Figure 1A) but also maintenance of the leukemic transforma-
tion, we transduced MLL-GAS7 full-blown leukemia cells from
primary transplanted mice (So et al., 2003b) with lentivirus co-
expressing a GFP marker and Prmt1 shRNA or a scramble con-
trol for in vitro and in vivo transformation assays. In contrast to
GFP-negative cells, which did not show any significant differ-
ence in colony-forming ability regardless of shRNA constructs
being used, GFP-positive cells carrying shPrmt1 had a severely
compromised colony-forming ability compared with their
scramble control (Figure 1G). The effectiveness of Prmt1 knock-
down was confirmed by both qRT-PCR on Prmt1 mRNA and
immunoblot on the associated H4R3me2as mark (Figure 1H).
To assess the in vivo leukemogenic function of Prmt1, we trans-
planted MLL-GAS7 cells into syngeneic mice for disease devel-
opment. Cohorts transplanted with Prmt1 knockdown leukemia
cells exhibited increased disease latency and a reduced pene-
trance compared with the scramble control (log-rank test
p < 0.0001) (Figures 1I, S1F, and S1G). Interestingly, the only
mouse transplanted with Prmt1 knockdown cells that suc-
cumbed to leukemia re-expressed high levels of Prmt1 and
Hoxa9 (Figure S1H), suggesting a high selective pressure
against Prmt1 knockdown for leukemia development. To further
address this point, we developed a Prmt1 Cre-ER conditional
knockout mouse where exons 5–6 spanning the catalytic
domain could be conditionally deleted upon tamoxifen treat-
ment, resulting in a truncated protein. Using primary c-kit+
HSPCs from this Prmt1flox/flox Cre-ER mouse for RTTA, we
observed an even more prominent suppression of MLL-GAS7
transformed cells both in vitro (Figures S1I and S1J) and in vivo
(Figure 1J) whereby none of the mice developed leukemia upon
Prmt1 deletion. Together, these independent approaches
confirm a critical function of Prmt1 in both leukemia initiation
and maintenance.
Pharmacological Inhibition of PRMT1 Suppresses AML
In Vivo
To further demonstrate the therapeutic potential of targeting
Prmt1, we examined the effect of an early-phase PRMT1 inhibi-
tor, AMI-408 (Bonham et al., 2010) (Figure S1K) on the suppres-
sion of MLL-GAS7 mediated leukemogenesis. Consistently,
treatment of MLL-GAS7 leukemia cells with AMI-408 resulted
in the reduction of H4R3me2as mark (Figure 1K) and reduced
colony-forming ability (Figure 1L). Importantly, in vivo adminis-
tration of AMI-408 to mice transplanted with pretreated MLL-
GAS7 leukemia cells significantly extended the survival and
reduced disease penetrance compared with the carrier control
(p = 0.0341) (Figure 1L), revealing the therapeutic potential of tar-
geting Prmt1 by a small-molecule inhibitor.
Recruitment of PRMT1 Is Indispensable for MOZ-TIF2-
Mediated Leukemogenesis
To further understand the functional role of Prmt1 in other leuke-
mia subtypes, we sought to dissect the roles of Prmt1 in MOZ-
TIF2-mediated transformation. Given that aberrant recruitment
of Prmt1 appears to be a common feature shared by different
MLL fusions, we intuitively examined the possible recruitment
of Prmt1 by MOZ-TIF2. Using immunoprecipitation assays, we
were able to show the specific interaction of MOZ-TIF2 with
both ectopically expressed and endogenous Prmt1 (Figure 2A).
To further demonstrate the in vivo functional interaction in
MOZ-TIF2 leukemic cells, ChIP analysis revealed specific
recruitment of Prmt1 and a high level of H4R3me2as mark on
the downstream targets of MOZ-TIF2, Hoxa9 loci (Katsumoto
et al., 2006; Kvinlaug et al., 2011), implicating a mechanistic sim-
ilarity among those PRMT1-dependent leukemic fusions (Fig-
ure 2B). To gain insights into this Prmt1 interaction, we prepared
variousMOZ-TIF2 deletionmutants, whichwere used tomap the
Prmt1 interaction domain by co-immunoprecipitation assays. As
a result, MOZ 50 was sufficient to recruit Prmt1, and deletion of its
N-terminal 310 amino acids (containing an N-terminal domain,
H15 and PHD) completely abolished the interaction (Figures
2C and 2D). Further progressive deletion analysis refined the first
79 amino acids of the N-terminal domain but not H15 and PHD of
the fusion as the minimal interaction domain required for Prmt1
recruitment, and conferring its epigenetic mark (Figures 2C–2E).
To examine the significance of Prmt1 interaction in leukemic
transformation, we performed structure-function analysis using
the corresponding MOZ-TIF2 deletion mutants to evaluate their
transformation ability (Figures 2D and S2A). An internal deletion
of H15 or PHD did not compromise cellular transformation,
whereas all the mutants with a deletion of the N-terminal Prmt1
interaction domain failed to transform HSPC (Figure 2D), consis-
tent with a critical function of Prmt1 recruitment for MOZ-TIF2
transformation. To further assess the requirement of Prmt1 for
leukemia maintenance, we transduced MOZ-TIF2 leukemic cells
carrying a ubiquitin C promoter (UbC)-driven luciferase reporter
(Becker et al., 2006) harvested from primary leukemia mice with
either shPrmt1 or scramble control lentivirus prior to transplanta-
tion into syngeneic mice for leukemia development. As a result,
in vivo imaging demonstrated reduced leukemia burdens for
mice carrying Prmt1 knockdown leukemic cells (Figure 2F).
Prmt1 knockdown also significantly extended the latency and
reduced penetrance of the disease compared with the control
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cohort (log-rank test p < 0.0001) (Figures 2F, S2B, and S2C).
Similar to the MLL-GAS7 studies, there was strong pressure
on select leukemia clones to escape from Prmt1 knockdown
as indicated by their re-expression of Prmt1, and Hoxa9 in
the leukemic mice received MOZ-TIF2 Prmt1 knockdown cells
(Figure S2B). Consistently, an irreversible inactivation of Prmt1
in MOZ-TIF2 transformed cells using conditional knockout
approach in RTTA not only significantly suppressed their
in vitro colony-forming ability (Figures S1I and S1J) but also abol-
ished their in vivo leukemogenic potentials (Figure 2G). To further
demonstrate the in vivo therapeutic potentials of targeting Prmt1
in the clinically relevant setting, we transplanted MOZ-TIF2 leu-
kemia cells carrying UbC-luciferase reporter without any pre-
treatment into syngeneic mice and then subjected them to
AMI-408 treatment. As expected, in vivo AMI-408 treatment
suppressed H4R3me2as mark in MOZ-TIF2 leukemia cells
(Figure 2H). More importantly, AMI-408 significantly reduced
the tumor burdens (Figure 2I) and extended the leukemia latency
(p = 0.0042) (Figure 2J). Although AMI-408 is an early-phase
PRMT1 inhibitor that clearly requires further optimization to
improve its potency, these results provide the proof-of-principle
experimental data showing in vivo efficacy of pharmacological
targeting of Prmt1 for leukemia suppression.
Aberrant Recruitment of PRMT1 Is Necessary but Not
Sufficient for Induction of AML In Vivo
While structure-function analysis, shRNA-mediated knockdown,
genetic knockout, and pharmacological inhibition experiments
clearly indicate an essential role of Prmt1 in MOZ-TIF2 leukemia,
it remains to be determined whether Prmt1 recruitment per se is
sufficient and the sole function of the N-terminal minimal trans-
formation domain required for MOZ-TIF2-mediated leukemo-
genesis. To this end, Prmt1 was covalently linked to transforma-
tion-defective MOZ-TIF2 N-terminal truncation mutants (DN79,
DN180, and D310) to examine whether Prmt1 swapping is suffi-
cient to resurrect their transformation activity. As a result, direct
fusion of Prmt1 to those transformation-defective N-terminal
deletion mutants was able to confer serial replating ability and
established primary transformed cell lines, albeit the number of
third-round colony was reduced (Figure 2D). In contrast, cova-
lent fusion of Prmt1 catalytically inactive mutant carrying a single
point mutation in the enzymatic domain failed to resurrect the
transformation ability of any of these N-terminal deletion MOZ-
TIF2 mutants (Figure 2D), despite their expression at a com-
parable level (Figure S2A). Immunophenotypic analysis of
the MOZ-TIF2-Prmt1 transformed cells confirmed the pheno-
types of early myeloid progenitors (c-kit, Gr1, and Mac1), which
were similar to wild-type (WT) MOZ-TIF2 leukemic cells (Fig-
ure 2K). We then tested whether Prmt1 swapping could
also rescue leukemogenesis in vivo by transplanting primary
HSPC immortalized with WT MOZ-TIF2 or MOZ-TIF2-Prmt1
(MT2DN79DAD2-Prmt1) into syngeneic mice for leukemia devel-
opment. Surprisingly, only mice transplanted with WTMOZ-TIF2
induced leukemia in vivo with a median disease latency of
61 days, whereas no leukemia was found in the cohort injected
with MOZ-TIF2-Prmt1 fusion immortalized cells (Figure 2L), sug-
gesting that additional hitherto unidentified molecules may also
be recruited by the N-terminal transformation domain and are
required for leukemogenesis.
MLL Fusions and MOZ-TIF2 Recruit KDM4C to Control
H3K9me3 Status of Their Target Genes
In addition to PMTs, KDMs frequently act in tandem with PMTs
for regulating gene expression critical for normal and disease
development (Cheung and So, 2011). This prompted us to
explore whether MOZ-TIF2 could interact and collaborate with
other KDMs to induce oncogenic transcriptional programs. To
this end, we performed a systematic biochemical screen to iden-
tify potential KDMs that may interact with MOZ-TIF2. Co-immu-
noprecipitation using MOZ-TIF2 and different KDMs revealed a
highly specific interaction with KDM4C but not any other tested
demethylases (Figure 3A). Reciprocal co-immunoprecipitation
experiments were then performed to map the KDM4C interac-
tion domain within MOZ-TIF2 using different deletion constructs
comprising the MOZ and TIF moiety of the fusion (Figure 3B).
KDM4C interactionwasmaintained byMOZ50 but not TIF 30 moi-
ety. Further deletion analysis refined the minimal KDM4C inter-
action domain within the first N-terminal 79 amino acids of
MOZ moiety, which overlaps with the PRMT1 interaction and
the aforementioned minimal N-terminal transformation domain.
Figure 2. Recruitment of Prmt1 by MOZ-TIF2 Is Necessary but Not Sufficient for HSPC Transformation
(A) Co-immunoprecipitation of FLAG-MOZ-TIF2 (fMT2) with myc-Prmt1 (upper) and endogenous Prmt1 (lower).
(B) ChIP analysis of H4R3me2as and Prmt1 localization on Hoxa9 promoter and gene body in MOZ-TIF2 after Prmt1 knockdown (KD).
(C) Co-immunoprecipitation of different FLAG-MOZ-TIF2 deletion mutants (indicated in D) and myc-Prmt1.
(D) RTTA to study the effect of N-terminal deletion mutants, active and inactive Prmt1 (P1) rescue fusions of MOZ-TIF2 on leukemic transformation.
(E) ChIP analysis of H4R3me2as mark on HOXA9 loci in HEK293 cells transfected with WT MOZ-TIF2 or DN79.
(F) Kaplan-Meier survival analysis of the effect of Prmt1 knockdown on MOZ-TIF2-mediated leukemogenesis (log-rank test p % 0.0001). Bioluminescence
imaging was performed at 21 days after transplantation. Median disease latency: control, 33 days; shPrmt1, undefined.
(G) Kaplan-Meier survival analysis of mice transplanted with WT or Prmt1 KO MOZ-TIF2 leukemia cells (log-rank test p = 0.0031). Median disease latency:
WT, 35 days; Prmt1 KO, undefined.
(H) Western blot analysis on the effect of AMI-408 on H4R3me2as, H3K4me3, and the loading control histone H3. Band intensity ratio was determined by
densitometry and normalized to vehicle control.
(I) Bioluminescence imaging of mice transplanted with MOZ-TIF2-luciferase leukemic cells 3 weeks after AMI-408 or carrier treatment.
(J) Kaplan-Meier survival analysis of AMI-408 and control treatment on MOZ-TIF2 leukemogenesis (log-rank test p = 0.0042). Median disease latency: control,
35.5 days; AMI-408, 48 days.
(K) Morphology of third-round colony of HSPC transformed by MOZ-TIF2 and its Prmt1 rescue fusion. FACS analysis of the transformed cells stained with c-kit,
Gr1, and Mac1. Scale bars represent 50 mm.
(L) Kaplan-Meier survival analysis of mice transplanted with MOZ-TIF2 or MT2DN79DAD2-P1 transformed cells (log-rank test p < 0.0001). Median disease
latency: MOZ-TIF2, 69 days; MT2DN79DAD2-P1, undefined.
All data shown are mean and SD (n = 3) unless otherwise specified. See also Figure S2.
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Figure 3. MOZ-TIF2 and MLL Fusions Recruits Kdm4c to Regulate H3K9 Methylation Status of Their Target Genes
(A–C) Co-immunoprecipitation of FLAG-KDMswithmyc-MOZ-TIF2 (A); FLAG-MOZdeletion constructs andmyc-KDM4C (B); FLAG-MLL fusions,MOZ-TIF2, and
AML1-ETO with myc-KDM4C (C).
(D) qRT-PCR analysis of Hoxa9 expression in murine leukemia cell lines.
(E) ChIP analysis of the H3K9me3 methylation on Hoxa9 loci of E2A-PBX (EP), MLL-AF9 (AF9), MLL-GAS7 (MG7), and MOZ-TIF2 (MT2).
(legend continued on next page)
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This leads to the hypothesis that KDM4C may represent the
additional epigenetic regulator that can cooperate with PRMT1
inmediating transcriptional deregulation and acute leukemogen-
esis. To this end, we further explored the role of KDM4C in other
PRMT1-dependent MLL oncoproteins, and were able to demon-
strate a strong interaction between KDM4C and MLL-GAS7
(Figure 3C). Biochemical mapping revealed the interaction
domain located at MLL 50, which is present in all MLL fusions.
Consistently, KDM4C was recruited by other MLL fusions such
as MLL-AF9 but not the non-MLL fusion control AML1-ETO
(Figure 3C).
To further demonstrate these interactions in vivo, we carried
out transcriptional and epigenetic analyses using HSPC trans-
formed by MLL fusions, MOZ-TIF2, or E2A-PBX control.
KDM4C is a lysine demethylase that catalyzes the specific
removal of the repressive H3K9 methylation marks and may be
required to maintain its target genes in an open chromatin
configuration for gene expression. In line with this hypothesis,
the level of H3K9me3 mark was inversely correlated with the
expression status of Hoxa9, a downstream transcriptional target
of both MLL fusions and MOZ-TIF2 (Figures 3D and 3E). In
contrast to the control E2A-PBX transformed cells, H3K9me3
mark on Hoxa9 loci was significantly lower in HSPC transformed
by MLL fusions or MOZ-TIF2 that recruited endogenous Kdm4c
to the promoter (Figures 3E and 3F). In addition, loss of
H3K9me3 was concomitant with the increased H3K9 acetylation
in MLL fusion or MOZ-TIF2 transformed cells (Figure S3A). To
gain further insights into the dynamic interplay of H3K9 methyl-
ation and KDM4C in transcriptional regulation, we employed
an inducible MLL-AF9-ER transformed primary cell line, in which
MLL-AF9 was fused to ER, allowing its activity to be regulated by
tamoxifen. Upon tamoxifen withdrawal, we detected signifi-
cantly reduced expression of MLL downstream targets including
Hoxa9 and Meis1 (Figure 3G) and a marked reduction of MLL
fusion binding to the Hoxa9 and Meis1 promoters (Figure S3B).
Lower MLL fusion binding also led to a concomitant reduced
recruitment of endogenous Kdm4c onHoxa9 andMeis1 loci (Fig-
ure 3H). Consistently, loss of Kdm4c binding was further accom-
panied by reduction of H3K9 acetylation and the accumulation of
repressive H3K9me3 and H3K27me3, indicating repressive tran-
scription complex domination in the absence of KDM4C (Fig-
ure 3I). Together, the results indicate that the dynamics of
H3K9 methylation and acetylation is tightly regulated by the
recruitment of KDM4C by the leukemic fusions.
Aberrant Transcriptional Networks Co-regulated by
KDM4C and PRMT1 in MLL and MOZ-TIF2 Leukemia
To investigate the transcriptional functions and potential
crosstalk between KDM4C and PRMT1 in acute leukemogen-
esis, we performed global transcriptional analyses by RNA
sequencing (RNA-seq) in both MOZ-TIF2 and MLL-GAS7 trans-
formed cells in the presence or absence of Kdm4c or Prmt1 us-
ing shRNA knockdown and conditional knockout approach,
respectively (Figures S4A and S4B). Differential expression
gene lists from two biological replicates were used to generate
heatmaps, which revealed highly similar and overlapping gene
expression signatures associated with the loss of Kdm4c and
Prmt1 (p = 1.97 3 1054 for MOZ-TIF2 and 5.71 3 1092 for
MLL-GAS7) (Figure 4A), consistent with their critical functions
in mediating transcriptional programs initiated by the fusions.
To gain further insights into the molecular pathways co-regu-
lated by these two epigenetic modifying enzymes, we deployed
gene set enrichment analysis (GSEA) to identify potential path-
ways perturbed by the loss of function of Kdm4c and Prmt1.
Consistently, a very large number of overlapping pathways
were perturbed by the loss of function of Prmt1 and Kdm4c (Fig-
ure 4B). As transcriptional activators, about 37% (201 of 548) of
the pathways activated by Kdm4c were also regulated by Prmt1
in MOZ-TIF2 transformed cells. Even more strikingly, 90% (201
of 222) of the pathways downregulated by Prmt1 inhibition
were also suppressed upon Kdm4c knockdown, suggesting a
strong transcriptional co-regulation mediated by these two
different classes of epigenetic modifying enzymes. We also
observed very similar transcriptional co-regulations between
Prmt1 and Kdm4c in MLL-GAS7 transformed cells, in which
52% (314 of 603) of Prmt1 activated pathways and 74% (314
of 427) of Kdm4c activated pathways were co-regulated by
each other (Figure 4B). These transcriptional analysis results
are also consistent with biochemical study showing that interac-
tion between Prmt1 and Kdm4c was largely dependent on MLL-
GAS7 and MOZ-TIF2 (Figure S4C), supporting the hypothesis
that these two epigenetic modifying enzymes are recruited by
the leukemic fusions to execute aberrant transcription programs.
KDM4C Is Required for Maintenance of Transcriptional
Programs by MLL Fusions
SinceMLL-AF9 recruits only Kdm4c but not Prmt1, we examined
whether suppression of Kdm4c was sufficient to interrupt the
oncogenic transcription programs maintained by the Prmt1-in-
dependent MLL fusion. Kdm4c knockdown in MLL-AF9 trans-
formed cells resulted in transcriptional signatures similar to
those in MLL-GAS7 transformed cells upon Prmt1/Kdm4c sup-
pression (Figures 4C and 4D). More than 35% (797 of 2,217,
p = 3.283 1057) of the genes and 60% (135 of 215) of the path-
ways significantly downregulated in MLL-AF9 transformed cells
upon Kdm4c knockdown overlapped with those in MLL-GAS7,
indicating a common requirement of Kdm4c in the maintenance
of transcription programs in different MLL leukemias. Interest-
ingly, there was a number of pathways commonly regulated by
both Prmt1 and Kdm4c in these fusions: these include the Myc
pathway and embryonic stem cell program (Figures 4E and
4F), which are important for MLL leukemia (Dawson et al.,
2011; Somervaille et al., 2009) and other AML (Zuber et al.,
2011). To validate some of the findings from RNA-seq, qRT-PCR
(F) ChIP analysis of Kdm4c localization at the promoter and gene body region of Hoxa9 in murine leukemia cell lines.
(G) qRT-PCR analysis of Hoxa9, Meis1, and Utx expression 4 days after tamoxifen withdrawal in the inducible MLL-AF9-ER cells.
(H) ChIP analysis of Kdm4c at the promoter and gene body regions of Hoxa9 and Meis1 loci of MLL-AF9-ER 4 days after tamoxifen withdrawal.
(I) ChIP analysis of H3K9me3, H3K27me3 (left) and acH3K9 and H3 (right) on the promoter and gene body regions of Meis1 4 and 6 days after tamoxifen
withdrawal.
All data shown are mean and SD (n = 3) unless otherwise specified. See also Figure S3.
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Figure 4. RNA-Seq Reveals Overlapping Pathways Targeted by Both Prmt1 and Kdm4c
(A) Heatmap analysis of gene expression profile in MOZ-TIF2 and MLL-GAS7 leukemic cells after Prmt1knockout and Kdm4c knockdown.
(B) Venn diagram showing the common downregulated pathways after the loss of function of Prmt1 and Kdm4c (overlapped) identified by GSEA.
(C) Heatmap analysis of gene expression signature perturbed in both MLL-AF9 and MLL-GAS7 after Kdm4c knockdown.
(legend continued on next page)
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experiments confirmed that Kdm4c knockdown resulted in the
suppression of expression of Myc as well as its target Bcat1 in
MLL-GAS7,MLL-AF9, andMOZ-TIF2 leukemia cells (Figure 4G).
Consistently, Kdm4c knockdown led to the upregulation of
H3K9me3 marks on Myc loci in MLL transformed cells (Fig-
ure 4H), indicating a critical function of KDM4C in regulating
oncogenic transcriptional networks.
KDM4C Is Essential for Initiation and Maintenance of
MLL and MOZ-TIF2 Leukemia
We next investigated the functional requirement of Kdm4c for
leukemic transformation. Suppression of Kdm4c by two inde-
pendent shRNAs (Figure S5A) resulted in a similar and significant
reduction of the serial replating ability of MLL fusions and MOZ-
TIF2 transformed cells compared with their relatively moderate
effect on E2A-HLF transformed cells (Figure 5A). Inhibition of
Kdm4c led to increased differentiation (Figure 5B), cell-cycle ar-
rest (Figure 5C), and apoptosis (Figure 5D), which are reminis-
cent to the effects of Prmt1 knockdown in MLL-GAS7 and
MOZ-TIF2 transformed cells (Figures S1C–S1E). Consistently,
Kdm4c knockdown in MLL fusions and MOZ-TIF2 transformed
cells resulted in the downregulation of Hoxa9 (Figure S5B) and
the increased level of H3K9me3 repressive marks (Figure S5C).
To further eliminate the possibility of any off-target effect of
Kdm4c shRNA attributed to the observed transformation pheno-
type, we co-expressed shRNA-resistant human KDM4C with
Kdm4c shRNA in MLL-AF9, MLL-GAS7, and MOZ-TIF2
leukemic cells. As a result, re-expression of KDM4C was able
to rescue the transformation defects associated Kdm4c shRNAs
(Figure S5D). To investigate whether Kdm4c is also required for
maintenance of leukemia in vivo, we transduced MLL fusions
and MOZ-TIF2 leukemia cells harvested from primary leukemic
mice with a scramble control or the Kdm4c shRNA prior to their
transplantation into syngeneic mice for disease development. 72
hours after transplantation, percentages of engraftment were
assessed and showed no significant difference between the
control and Kdm4c knockdown cells, indicating that Kdm4c
knockdown has rather limited impact on homing of the leukemic
cells (Figure 5E). In contrast to mice transplanted with control
transducedMLL-GAS7 leukemic cells that all succumbed to leu-
kemia within 6 weeks, Kdm4c knockdown in leukemic cells abol-
ished their oncogenic activity, and all mice remained healthy
even after 14 weeks of observation (Figures 5F and S5E–S5G).
Similarly, inhibition of Kdm4c expression significantly delayed
disease latency of MOZ-TIF2-induced leukemia (log-rank test
p < 0.0001, Figures 5F and S5E–S5G). More importantly, we
also observed drastic inhibition of the leukemogenic potentials
of Prmt1-independent MLL-AF9 fusion, leading to a significant
improvement of the disease-free survival and reduced pene-
trance (log-rank test p < 0.0001, Figures 5F and S5E–S5G).
Similar to Prmt1 in vivo knockdown data, the few leukemias
from the mice that received Kdm4c-knockdown cells actually
re-expressed high levels of Kdm4c and Hoxa9 (Figure S5H),
indicating a strong growth disadvantage of Kdm4c knockdown
leukemia cells. Together, these results highlight an essential
function of Kdm4c in leukemias driven by MLL fusions and
MOZ-TIF2.
To further investigate the potential therapeutic window of
targeting Kdm4c in the hematopoietic system, we assessed
the impact of Kdm4c suppression in normal hematopoiesis.
Kdm4c knockdown in c-kit+ HSPCs did not lead to any signifi-
cant reduction of colony-forming ability (Figure 5G) or any
change in their ability to differentiate into different lineages (Fig-
ure 5H) in vitro. To assess the effect of Kdm4c suppression on
in vivo hematopoietic development, we transplanted Kdm4c
knockdown HSPCs into sublethally irradiated syngeneic mice
for in vivo repopulation assay. Consistent with in vitro data,
Kdm4c knockdown cells competently reconstituted the hemato-
poietic systems (Figure 5I) and gave rise to multiple hematopoi-
etic lineages (including myeloid, B-lymphoid, and T-lymphoid) in
a fashion indistinguishable to that in controls 6 weeks after the
transplantation (Figure 5J). These results are in line with the
dispensable embryonic function of Kdm4c for development
into phenotypically normal Kdm4c knockout mouse (Pedersen
et al., 2014), suggesting a potential therapeutic window for tar-
geting Kdm4c for leukemia suppression.
Pharmacological Inhibition of Kdm4c Suppresses
Leukemia Development in Both SyngeneicMouseModel
and Human AML Xenograft Model
To further demonstrate the therapeutic potentials of targeting
KDM4C in AML, we tested the leukemia inhibitory activity of a
newly developed KDM4C inhibitor, SD70 (Jin et al., 2014). Using
mouse primary cells transformed by MLL fusions and MOZ-TIF2
as the model systems, SD70 was able to significantly suppress
their cell growth (Figure 6A), and induced apoptosis (Figure 6B),
differentiation (Figure 6C), and cell-cycle arrest (Figure 6D),
which are consistent with the effects of Kdm4c knockdown in
these cells (Figures 5A–5D). To further access the in vivo efficacy
of SD70 treatment, we transplantedMLL-AF9 leukemia cells car-
rying a luciferase reporter into irradiated syngeneic mice for
in vivo treatment with either vehicle control or SD70. By in vivo
imaging 6 weeks after the transplant, we detected significant
leukemic burdens in the vehicle-treated cohort (Figure 6E). In
contrast, SD70 drastically suppressed leukemic burdens (Fig-
ure 6E) and, more importantly, significantly extended the disease
latency (Figure 6F). Consistent with Kdm4c knockdown data,
SD70 was able to suppress H3K9me3 activity in vivo (Figure 6G)
and inhibited the expression of MLL downstream target genes
(Figure S6A).
To determine whether SD70 can also be effective in human
MLL leukemia, we treated various human leukemia cell lines
(D) Venn diagram showing the commonly downregulated genes on MLL-AF9 and MLL-GAS7 after Kdm4c knockdown (left) as well as commonly downregulated
pathways identified by GSEA (right).
(E) Embryonic stem cell signature and Myc pathway were downregulated after the loss of Prmt1 or Kdm4c in both MOZ-TIF2 (left) and MLL-GAS7 (right).
(F) Embryonic stem cell signature and Myc pathway were downregulated in both MLL fusions after Kdm4c knockdown.
(G) qRT-PCR analysis of Myc and Bcat1 expression after Kdm4c knockdown.
(H) ChIP analysis showing the effect of Kdm4c knockdown on H3K9me3 mark in Myc loci of MLL-AF9 leukemia cells.
All data shown are mean and SD (n = 3) unless otherwise specified. See also Figure S4.
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carrying different genetic mutations with SD70. As a result, we
observed a specific and preferential suppression on human leu-
kemia cell lines carrying MLL fusions (such as SEM and THP1)
over the non-MLL leukemia cell lines (Figure 6H). Consistent
with the data onmouse primary transformed cells, SD70 induced
apoptosis (Figure 6I), differentiation (Figure S6B), and cell-cycle
arrest (Figure S6C) accompanied with an increased level of
H3K9me3mark (Figure S6D) in MLL leukemia cell lines, suggest-
ing a similar requirement of KDM4C activity in both human and
mouse MLL leukemias.
To further demonstrate the utility of KDM4C inhibitor on the
most relevant preclinical setting, we deployed primary AML cells
from patients carrying MLL fusions for both in vitro and in vivo
drug treatment studies. As a result, we observed that MLL pri-
mary leukemia cells (i.e., MLL1-3) were highly sensitive to SD70
(Figures 6J and 6K). A low dose of SD70 (500 nM) efficiently sup-
pressed proliferation (Figure 6J) and induced differentiation (Fig-
ure 6K) of primary AML cells carrying MLL fusions (i.e., MLL1-3)
but not the control primary AML primary cells without the translo-
cations (non-MLL1-4). To further assess the effects of SD70 on
leukemia cell growth and disease development in vivo, we
labeled the primary AML cells carrying MLL fusion (MLL3) with
a luciferase reporter prior to their transplantation into NSG mice
for either the vehicle or SD70 in vivo treatment. Sevenweeks after
transplantation, in vivo bioluminescence imaging revealed a
rapid leukemic growth and disease onset in the control cohort
(Figure 6L). In contrast, the SD70-treated cohort hadmuch lower
tumor burdens (Figure 6L). More importantly, while the entire
control cohort succumbed to leukemia within 59 days (Figures
6M, S6E, and S6F), the SD70-treated group did not show any
sign of the disease and all mice survived throughout the ob-
servation period (Figures 6M, S6E, and S6F). These results could
also be faithfully reproduced using an independent KDM4C
shRNA approach on the human MLL3 primary leukemia cells
(Figure S6G), where the control cohort with scramble shRNAsuc-
cumbed to leukemia with a short latency whereas the entire
KDM4C knockdown group survived throughout the 90-day
observation period (Figure S6G). Together, these results provide
the molecular and preclinical evidence for the potential clinical
utility of SD70 in MLL leukemia.
DISCUSSION
Elucidation of the mechanisms that orchestrate epigenetic re-
programming by oncogenic transcription factors is critical for un-
derstanding the molecular biology of the disease and designing
effective therapeutic strategies (Cheung and So, 2011). In this
study, we describe the co-recruitment of Prmt1 and Kdm4c by
MLL-GAS7 andMOZ-TIF2, which exemplifies the dynamic inter-
play and cooperation between histone code writers and erasers
for execution of specific transcriptional programs mediated by
oncogenic transcription factors in acute leukemia (Figure 7). His-
tone methylation and demethylation as a key component of his-
tone code is on constant flux, and perturbation of this dynamic
event on chromatin can shift the equilibrium to alter transcription
outcomes. While the collaboration between KMTs and KDMs
(e.g., between MLL and JMJD3) (Agger et al., 2007) has been
previously documented to facilitate the switch between different
transcriptional states by reinforcing specific histone methylation
codes on lysine residues (Cheung and So, 2011; Cloos et al.,
2008), our study suggests that similar mechanisms also operate
between histone arginine and lysine methylations. H4R3me2as
encodes an activation mark that allows recruitment of histone
acetyltransferases such as CBP and p300 to open up the chro-
matin structure for gene expression (An et al., 2004; Cheung
et al., 2007). To facilitate such a modification, the lysine residues
subjected to acetylation should be free from methyl groups.
Consistently, recruitment of KDM4C mediates the removal of
H3K9me3 repressive mark, allowing the replacement with the
activating acetylation mark, suggesting that a coordinated func-
tional recruitment of multiple distinctive epigenetic modifying en-
zymes is required for establishment of oncogenic transcriptional
programs mediated by chimeric transcription factors in cancer
development.
As proof of principle, we provide the long-sought-after in vivo
preclinical data showing that inhibition of Prmt1 activity by
shRNA or chemical inhibitor approaches can significantly sup-
press oncogenic transformation mediated by various AML fu-
sions, and extend the latency of established disease in the
transplanted animals. In recent years, PRMT1 has been impli-
cated in AML1-ETO leukemia (Shia et al., 2012) and some solid
tumors (Mathioudaki et al., 2011; Yoshimatsu et al., 2011);
however, in vivo transformation data are still required to firmly
establish a functional link in the actual disease pathogenesis.
The current establishment of an in vivo preclinical model pro-
vides a strong rationale and platform to evaluate and develop
more specific Prmt1 inhibitors in the future for targeted cancer
therapy. Compared with BCR-ABL in CML and PML-RARa in
APL, we have an extremely limited knowledge about the molec-
ular functions of PMTs in normal and cancer development
Figure 5. Suppression of Kdm4c Inhibits Hematopoietic Transformation and Leukemogenesis
(A) RTTA showing the effect of two different Kdm4c shRNAs on leukemic transformation.
(B) FACS analysis showing the effect of Kdm4c knockdown on Mac1 expression.
(C) Cell-cycle analysis after Kdm4c knockdown.
(D) Apoptosis analysis after Kdm4c knockdown.
(E) Murine leukemia cells were transduced with the control or shKdm4c lentivirus and transplanted into syngeneicmice. Bonemarrows were harvested after 72 hr
and the percentage of donor cells was determined by FACS.
(F) Kaplan-Meier survival analysis on the effect of Kdm4c knockdown (shKdm4c#1) on leukemogenesis (log-rank test p < 0.0001). Median disease latency: control
MLL-AF9, 31 days; MLL-GAS7, 37 days; MOZ-TIF2, 33 days; shKdm4c, undefined.
(G) Effect of Kdm4c knockdown on the colony-forming ability of HSPC. Scale bar represents 0.5 cm.
(H) CFU assay showing the effect of Kdm4c knockdown on the types and number of myeloid colonies derived from HSPC. Scale bar represents 0.5 cm.
(I) FACS analysis of HSPC engraftment using CD45.1 marker to detect the donor cell populations in peripheral blood 6 weeks after transplantation (n = 5).
(J) FACS analysis of the effect of Kdm4c knockdown on both myeloid (left) and lymphoid populations (right) in peripheral blood (n = 5).
All data shown are mean and SD (n = 3) unless otherwise specified. See also Figure S5.
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despite a preliminary indication of clinical efficacy of the KMT in-
hibitor against DOT1L in the phase I trial. The lessons from ima-
tinib on CML (Balabanov et al., 2014) and ATRA on APL (Fung
and So, 2013) indicate that the development of drug-resistant
clones after achieving an initial clinical remission by highly effec-
tive and specific inhibitors against a particular molecule will be a
major issue for most of the targeted therapies. Understanding
themechanisms of action is essential, and has been instrumental
in designing more effective therapeutic strategies to minimize
and overcome relapses (Cortes et al., 2012; Lo-Coco et al.,
2013). The discovery of the functional crosstalk between
PRMT1 and KDM4C in the establishment of an oncogenic tran-
scriptional program in leukemia provides important insights
into the molecular functions and underlying mechanisms of
these critical PMTs and KMDs in oncogenesis.
The dynamics of H3K9methylation is regulated by the intricate
equilibrium of lysine methyltransferases and demethylases. Us-
ing in vitro cell line models, KDM4C has been implicated in
different cancers including squamous cell carcinoma (Cloos
et al., 2006), B-cell lymphoma (Rui et al., 2010), and prostate
(Wissmann et al., 2007), and breast (Liu et al., 2009) cancers.
Loss of Suv39h resulted in a reduction of H3K9me3 mark and
accelerated tumor development (Braig et al., 2005; Peters
et al., 2001), suggesting a tumor-suppressor function associated
with H3K9me3 in critical but unknown loci. Consistent with this
model, recruitment of KDM4C by chimeric transcription factors
Figure 6. SD70 Inhibits Leukemogenesis In Vitro and In Vivo
(A) Murine leukemia cells were treated with SD70 or DMSO for 3 days with cell viability determined by trypan blue exclusion assay.
(B) Apoptosis analysis on SD70- or DMSO-treated murine leukemia cells.
(C) FACS analysis of myeloid marker Mac1 in murine leukemia cells after SD70 treatment.
(D) Cell-cycle analysis after SD70 treatment.
(E) MLL-AF9-luciferase leukemia cells were transplanted into syngeneic mice and subjected to either vehicle control or SD70 treatment. Bioluminescence
imaging was performed at 39 days after transplantation.
(F) Kaplan-Meier survival analysis on the effect of SD70 treatment on MLL-AF9 mediated leukemogenesis (log-rank test p = 0.0143). Median disease latency:
control, 55 days; SD70, 61.5 days.
(G) Western blotting analysis of H3K9me3 mark in murine MLL-AF9 leukemia cells after SD70 in vivo treatment. Intensity ratio was determined by densitometry.
(H) Cell viability of human leukemia cell lines were determined 3 days after SD70 or DMSO treatment.
(I) Apoptosis analysis of SD70-treated human leukemia cell lines.
(J) Cell viability of primary AML patient samples after SD70 treatment (MLL, n = 3; non-MLL, n = 4).
(K) NBT reduction assay to determine myeloid differentiation of MLL and non-MLL patient samples. The black bars show the mean.
(L) Primary humanMLL leukemia (MLL3) was taggedwith luciferase reporter and then transplanted into NSGmice. Bioluminescence imaging of control (n = 6) and
SD70-treated (n = 5) cohorts were performed on day 44 after transplantation. Bars show the mean bioluminescence intensity.
(M) Kaplan-Meier survival analysis of vehicle or SD70-treated cohort transplanted with primary human MLL3 leukemia cells (log-rank test p = 0.0018). Median
disease latency: control, 59 days; SD70, undefined.
All data shown are mean and SD (n = 3) unless otherwise specified. See also Figure S6.
Figure 7. Schematic Diagram Summarizes Aberrant Epigenetic Networks and Therapeutic Potentials of Targeting PRMT1 and KDM4C
in AML
Left panel indicates the aberrant recruitment of PRMT1 and KDM4C by MLL fusions and MOZ-TIF2 to drive oncogenic transcriptional programs. Panels on the
right depict the potential targeting of epigenetic modifying enzymes for leukemia suppression. MLL fusions in the diagram refer to MLL-GAS7 and MLL-EEN,
although KDM4C inhibition can also be effective for other MLL fusions including MLL-AF9.
Cancer Cell 29, 32–48, January 11, 2016 ª2016 Elsevier Inc. 45
can counteract and remove the repressive H3K9 trimethylation
marks on their target gene loci such as Hoxa9, which are critical
for self-renewal and oncogenic transformation. This is supported
by the concomitant increase in H3K9me3 mark and suppression
of Hoxa9 expression upon Kdm4c knockdown. Recently,
H3K9me2/1 demethylase PHF8 has been shown to govern
ATRA treatment response in APL, and its activation helps to
overcome treatment resistance (Arteaga et al., 2013). Our cur-
rent studies provide the key in vivo experimental evidence
demonstrating the requirement of KDM4C for cancer develop-
ment and its functional crosstalk with PRMT1 in the establish-
ment of histone codes for transcriptional deregulation in AML.
Intriguingly, suppression of either of the epigenetic regulators
compromises transcriptional programs and cellular transforma-
tion by MOZ-TIF2 or MLL-GAS7 fusions, indicating their critical
and non-overlapping functions that are indispensable for the
oncogenic transformation (Figure 7). This is also consistent
with the finding that KDM4C is required for PRMT1-independent
MLL leukemia. Importantly, transcriptional or pharmacological
inhibition of KDM4C by molecular or small-molecule inhibitor
approaches could significantly lower leukemic burdens and
extend the disease latency, particularly in anMLL primary human
AML cell xenograft in vivo model. Together, these findings
provide strong experimental and preclinical in vivo evidence
demonstrating an efficient MLL leukemia suppression by
pharmacological inhibition of KDM4C, laying the foundation for
future clinical application of KDM4C inhibitors in human cancer
treatments.
Advancement in our knowledge of onco-epigenomics,
together with the dissection of the dynamic interplay of chro-
matin modification and remodeling mediated by leukemic tran-
scription factors, could pave the way to revolutionize our
therapeutic options. Cracking the lethal histone code created
by leukemic fusions and a strategy of rational therapeutic design
targeting specific epigenetic modifying enzymes required for the
oncogenic transcription factors hold the promise of eradicating
this devastating disease.
EXPERIMENTAL PROCEDURES
In Vitro and In Vivo Transformation Studies
RTTA was performed as previously described (Zeisig and So, 2009) and is
detailed in Supplemental Experimental Procedures. For Kdm4c knockdown
rescue experiments, cells were co-transduced with Kdm4c shRNA and
shRNA-resistant human KDM4C lentiviruses, and co-selected with puromycin
and blasticidin. To generate full-blown murine leukemia cells, we injected 106
immortalized cells via the tail vein into sublethally irradiated syngeneic
C57BL/6 mice. Mice were injected with 105 murine leukemia cells to study
the effect Prmt1 and Kdm4c knockdown on leukemogenesis. Leukemia cells
were transduced with either control or shPrmt1 retrovirus, and GFP sorted
before transplantation. Kdm4c knockdown cells were selected with antibiotic
prior to transplantation. Prmt1 knockout induced by tamoxifen were confirmed
by PCR genotyping prior to transplantation. Mice were monitored for develop-
ment of leukemia by fluorescence-activated cell sorting (FACS) analysis with
tissues processed for histological analysis. Primary human MLL3 leukemia
cells were transduced with control or shKDM4C lentivirus, and antibiotic
selected and transplanted (105) by intrafemoral injection into sublethally irradi-
ated NOD/SCID/IL2Rg/ (NSG) mice. For bioluminescence imaging and
quantification of leukemia burden, murine leukemias were established using
HSPC isolated from Ubc-luciferase reporter mice (Becker et al., 2006),
whereas human leukemia was tagged with a lentiviral luciferase reporter.
Transplantedmicewere injectedwith 150mg/kg of D-luciferin intraperitoneally
and bioluminescence image acquired using IVIS Lumina II (Caliper; Perkin
Elmer) with software Living Image Version 4.3.1 according to the manufac-
turer’s instructions. All the animal works were performed according to the
guidelines and regulations of the Animal (Scientific Procedures) Act 1986,
and approved by the KCL local ethics committee.
AMI-408 Drug Treatment
For AMI-408 drug treatment in vitro, 104 cells were plated in methylcellulose
with 200 mM AMI-408 or DMSO control and cultured for 5–7 days. To study
the effect of AMI-408 on leukemogenesis of MLL-GAS7 in vivo, we pretreated
leukemia cells in vitro with the drug for 24 hr prior to injection. 105 MLL-GAS7
leukemia cells were then transplanted into C57BL/6 mice via tail vein and in-
jected intraperitoneally with 20 mg/kg of AMI-408 or carrier control every other
day for 2 weeks. To study the effect of AMI-408 on MOZ-TIF2 leukemogenesis
in vivo, we transplanted 105 leukemia cells into syngeneic C57BL/6 mice via
tail vein injection without pretreatment. Mice were subjected to a dosage of
10 mg/kg of AMI-408 in PEG300/D5W for 4 weeks with five consecutive injec-
tions per week. Bioluminescence imaging was performed every week.
SD70 Drug Treatment
Leukemia cells were seeded at 5 3 104/ml and incubated with SD70 (Xcess
Biosciences) at a concentration of 0.8 mM for human cell lines, 2 mM for murine,
and 0.5 mM for primary human samples for 48–72 hr. To study the effect of
SD70 on leukemogenesis in vivo, we transplanted 105 murine MLL-AF9-lucif-
erase leukemia cells 3 days prior to treatment. Human primary leukemia MLL3
was transplanted by intrafemoral injection into sublethally irradiated NSGmice
3 days before drug treatment. SD70 preparation and drug dosage used for
in vivo animal experiments were performed as described by Jin et al. (2014).
SD70 was administered intraperitoneally at 10 mg/kg in PEG300/D5W for
4 weeks with five consecutive injections in the first week and every alternative
day for the next 3 weeks. Sick mice were euthanized and processed for FACS
and histological analysis. SD70-treated mice were injected with 50 mg/kg of
SD70 intraperitoneally, and bone marrow was harvested 5 hr later for western
blot analysis.
Statistical Analysis
All the experiments were analyzed using two-way Student’s t test. For the
comparison of different specimens the unpaired t test was used. For the com-
parison of different treatments (e.g., drug, gene knockdown/knockout) within
the same specimen, the paired t test was used. The log-rank test was used
to compare survival curves. p Values of less than 0.05 were considered statis-
tically significant. In the figures, asterisks indicate *p < 0.05, **p < 0.01, and
***p < 0.001. For the RNA-seq analysis, differentially expressed genes with
p < 0.05 were used to generate heatmaps. The statistical significance of over-
lap between the gene expression patterns of two conditions was calculated
using a hypergeometric test (Marioni et al., 2008).
Additional experimental procedures including description of plasmids, cell
lines, conditions for qRT-PCR, GST pull-down assay, immunoprecipitation,
chromatin immunoprecipitation, NTB reduction assay, flow cytometry, gener-
ation of Prmt1 conditional knockout mouse, RNA-seq, and RNA analysis are
reported in Supplemental Experimental Procedures.
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